Additionally, the combination altered the tumor microenvironment by reducing immunosuppressive cell populations, including tumor-associated macrophages and regulatory T cells, which are typically increased following BRAF inhibitor therapy alone. The gene discussed is BRAF; the disease is neoplasm.